1. 2022-RA-296-ESGO Non-pharmacological, patient-related predictive model for the occurrence of CINV: prospective, multicentre study in Germany (NOGGO-EMRISK trial). (20th October 2022) Authors: Sehouli, Jalid; Oskay-Özcelik, Gülten; Zocholl, Dario; Klemt, Anna-Sophia; Bangemann, Nikola; Albrecht, Oliver; Strittmatter, Hans-Joachim; Wimberger, Pauline; Kaczerowsky, Anna; Lorenz, Ralf; Ruhwedel, Wencke; Fehm, Tanja; Zahn, Andreas; Tomé, Oliver; Markert, Miriam; Hager, Dietrich; Zorr, Andr... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2022-RA-835-ESGO AGO-OVAR 2.34/MIROVA: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. (20th October 2022) Authors: Trillsch, Fabian; Schochter, Fabienne; Park-Simon, Tjoung-Won; Reuß, Alexander; Fehm, Tanja; Wimberger, Pauline; Bronger, Holger; Schmalfeldt, Barbara; Sehouli, Jalid; Marmé, Frederik; Heitz, Florian; Mahner, Sven; Fredrich, Michaela; Barth, Stefanie; Stec, James; Method, Michael; Harter, Philipp Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 295 Accumulation of 53BP1 in circulating tumor cells during treatment with eribulin identifies chemotherapy-responsive metastatic breast cancer patients. (4th December 2020) Authors: Schochter, Fabienne; Werner, Kim; Köstler, Cäcilia; Müller, Volkmar; Neubauer, Hans; Fehm, Tanja; Friedl, Thomas WP; Polzer, Bernhard; Janni, Wolfgang; Wiesmüller, Lisa Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 4 Page Start: A98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 86: Predictive Factors of Survival After Neoadjuvant Radiotherapy and Chemotherapy in High-Risk Breast Cancer. (October 2021) Authors: Matuschek, Christiane; Budach, Wilfried; Tamaskovics, Balint; Fischer, Johannes; Boelke, Edwin; Corradini, Stefanie; Kammers, Kai; Kraemling, Carolin Nestle; Fehm, Tanja; Wollandt, Sylvia; Speer, Vanessa; Haussmann, Jan Journal: Radiotherapy and oncology Issue: Volume 163(2021)Supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro. (November 2017) Authors: Thomssen, Christoph; Decker, Thomas; Fehm, Tanja; Fuxius, Stefan; Harbeck, Nadia; Juhasz-Böss, Ingolf; Möbus, Volker; Seehase, Martina; Schollenberger, Lukas; Ruckes, Christian; Schmidt, Marcus Journal: Breast Issue: Volume 36(2017)Supplement 1 Page Start: S51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer. Issue 1 (31st July 2014) Authors: Sänger, Nicole; Ruckhäberle, Eugen; Györffy, Balazs; Engels, Knut; Heinrich, Tomas; Fehm, Tanja; Graf, Anna; Holtrich, Uwe; Becker, Sven; Karn, Thomas Journal: Molecular oncology Issue: Volume 9:Issue 1(2015:Jan.) Page Start: 58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Acute hepatitis C virus infection induces anti‐host cell receptor antibodies with virus‐neutralizing properties. Issue 3 (28th July 2015) Authors: Tawar, Rajiv G.; Colpitts, Che C.; Timm, Jörg; Fehm, Tanja; Roggendorf, Michael; Meisel, Helga; Meyer, Nicolas; Habersetzer, François; Cosset, François‐Loïc; Berg, Thomas; Zeisel, Mirjam B.; Baumert, Thomas F. Journal: Hepatology Issue: Volume 62:Issue 3(2015:Sep.) Page Start: 726 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases. Issue 2 (19th June 2012) Authors: Todenhöfer, Tilman; Hennenlotter, Jörg; Schmiedel, Benjamin Joachim; Hohneder, Andrea; Grimm, Sabrina; Kühs, Ursula; Salih, Helmut Rainer; Bühring, Hans‐Jörg; Fehm, Tanja; Gakis, Georgios; Blumenstock, Gunnar; Aufderklamm, Stefan; Schilling, David; Stenzl, Arnulf; Schwentner, Christian Journal: Prostate Issue: Volume 73:Issue 2(2013) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Issue 5 (13th July 2013) Authors: Schneck, Helen; Blassl, Christina; Meier-Stiegen, Franziska; Neves, Rui Pedro; Janni, Wolfgang; Fehm, Tanja; Neubauer, Hans Journal: Molecular oncology Issue: Volume 7:Issue 5(2013:Oct.) Page Start: 976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020) Authors: Pfisterer, Jacobus; Shannon, Catherine M; Baumann, Klaus; Rau, Joern; Harter, Philipp; Joly, Florence; Sehouli, Jalid; Canzler, Ulrich; Schmalfeldt, Barbara; Dean, Andrew P; Hein, Alexander; Zeimet, Alain G; Hanker, Lars C; Petit, Thierry; Marmé, Frederik; El-Balat, Ahmed; Glasspool, Rosalind; de... Journal: Lancet oncology Issue: Volume 21:Issue 5(2020) Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗